Vascular Biogenics Ltd. VBLT
We take great care to ensure that the data presented and summarized in this overview for Vascular Biogenics Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in VBLT
Top Purchases
Top Sells
About VBLT
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Insider Transactions at VBLT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 08
2024
|
Tuomo Patsi Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,247
+50.0%
|
-
|
|
May 08
2024
|
Michele Galen Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,247
+50.0%
|
-
|
|
May 08
2024
|
Peter Feinberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,247
+50.0%
|
-
|
|
May 08
2024
|
Thomas Graney Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,247
+50.0%
|
-
|
|
May 08
2024
|
Thomas I H Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,247
+50.0%
|
-
|
|
May 08
2024
|
Thomas Bock Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+50.0%
|
-
|
|
Jan 02
2024
|
Fr Capital Holdings, L.P. |
SELL
Open market or private sale
|
Indirect |
50,000
-5.37%
|
$50,000
$1.89 P/Share
|
|
Dec 29
2023
|
Fr Capital Holdings, L.P. |
SELL
Open market or private sale
|
Indirect |
6,000
-0.64%
|
$6,000
$1.83 P/Share
|
|
Dec 28
2023
|
Fr Capital Holdings, L.P. |
SELL
Open market or private sale
|
Indirect |
21,500
-2.24%
|
$43,000
$2.01 P/Share
|
|
Dec 27
2023
|
Fr Capital Holdings, L.P. |
SELL
Open market or private sale
|
Indirect |
20,033
-2.05%
|
$40,066
$2.08 P/Share
|
|
Dec 26
2023
|
Fr Capital Holdings, L.P. |
SELL
Open market or private sale
|
Indirect |
11,456
-1.16%
|
$22,912
$2.16 P/Share
|
|
Dec 22
2023
|
Fr Capital Holdings, L.P. |
SELL
Open market or private sale
|
Indirect |
45,000
-4.35%
|
$90,000
$2.41 P/Share
|
|
Dec 21
2023
|
Fr Capital Holdings, L.P. |
SELL
Open market or private sale
|
Indirect |
2,867
-0.28%
|
$5,734
$2.51 P/Share
|
|
Mar 31
2023
|
Samuel Backenroth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
525,000
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 626K shares |
|---|
| Open market or private sale | 157K shares |
|---|